Table 2.
Scientific Events Leading to Advent of 5α-Reductase Inhibitors
| Investigator | Era | Discovery |
|---|---|---|
| J. Hunter (Scotland)17 | 1786 | Prostate dependence on testes |
| A. Berthold (Germany) | 1849 | Blood-borne nature of testosterone; first |
| (http ://www.usrf.org) | hormone | |
| L. Ruzicka (Switzerland) & | 1939 | Isolation, synthesis of testosterone; |
| A. Butenandt (Germany)16 | Nobel Prize, 1939 | |
| C.B. Huggins (US)20,21 | 1941 | Responsiveness of prostate diseases to |
| androgen deprivation therapy; | ||
| Nobel Prize, 1966 | ||
| J. Wilson (US)23 | 1969 | Biologic role of DHT |
| J. Imperato-McGinley (US)1 | 1974 | Effects of congenital deficiency of 5AR |
| P.C. Walsh (US)26 | 1975 | Co-discovery of 5AR syndrome |
| E. Stoner,28 | 1992 | Approval of finasteride |
| G. Gormley (US)29 | ||
| R. Rittmaster,30 | 2002 | Approval of dutasteride |
| C. Roehrborn (US)14 |
DHT, dihydrotestosterone; 5AR, 5α-reductase.